美国Hemostemix公司与CytoImmune Therapeutics合作,在波多黎各生产ACP-01治疗心脏病的产品. Hemostemix Inc. partners with CytoImmune Therapeutics for ACP-01 heart disease treatment production in Puerto Rico.

Hemostemix Inc.,一家干细胞治疗公司,宣布与CytoImune治疗公司签订《制造服务协定》,以恢复CytoImmune在波多黎各先进设施的ACP-01生产。 Hemostemix Inc., a stem cell therapy firm, announces a Manufacturing Services Agreement with CytoImmune Therapeutics to revive ACP-01 production at CytoImmune's advanced facility in Puerto Rico. ACP-01,心脏病患者的治疗,将心脏功能增加27%。 ACP-01, a treatment for heart disease patients, increases heart function by 27%. 该合作旨在帮助患者并为Hemostemix股东创造现金流,预计在2025年第一季度开始ACP-01治疗. The partnership aims to help patients and generate cash flow for Hemostemix shareholders, with ACP-01 therapy expected in Q1 2025.